Galera Therapeutics Sells Assets to Biossil Inc.
I'm PortAI, I can summarize articles.
Galera Therapeutics has sold its dismutase mimetic assets, including avasopasem and rucosopasem, to Biossil Inc. under an Asset Purchase and Sale Agreement dated October 15, 2025. The transaction, completed by October 21, 2025, transfers financial liabilities to Biossil. Spark's analysis rates GRTX as Underperform, citing significant financial instability, consistent losses, and negative equity, leading to a bearish market outlook. Galera focuses on developing innovative therapeutics in the biopharmaceutical sector, with a current market cap of $1.78M and an average trading volume of 125,397.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments